{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"160.900","rs_stock_flag":false,"fiscal_year_end":"2025年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"301,666,673","primaryexch":"香港交易所","ric":"2617.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BTML3Y8","am":"210.42","iv":"","ew_strike":"","as":"144.100","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"143.100","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"20.200","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"吳永謙","underlying_ric":"2617.HK","hi52":"679.500","issuer_name":"藥捷安康(南京)科技股份有限公司 - B - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"143.000","mkt_cap":"43.19","f_aum_hkd":null,"ew_sub_per_to":"","ls":"143.200","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-16.600","aum":"","issued_shares_class_B":null,"vo":"1.41","secondary_listing_flag":false,"listing_date":"2025年6月23日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"藥捷安康(南京)科技股份有限公司 - B - H股","nm_s":"藥捷安康－Ｂ","sym":"2617","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.100","strike_price":"","summary":"藥捷安康（南京）科技股份有限公司是一家從事生物製藥的中國公司，主要專注於發現及開發腫瘤、炎症及心臟代謝疾病小分子創新療法。該公司的核心產品Tinengotinib是一種處於註冊臨牀階段的內部發現和開發的MTK抑制劑，適用於某些復發或難治的耐藥實體瘤。該公司的腫瘤產品線包括TT-00973（針對 AXL）、TT-01488（用於血液系統惡性腫瘤）、TT-01688（用於炎症性疾病）和TT-00920（用於慢性心力衰竭）。這些產品能夠對多種癌症類型（包括前列腺癌、肝癌、乳腺癌和BTC）產生療效。它還可用於治療肝細胞癌、乳腺癌、膽道癌和Pan-FGFR實體瘤。","op":"160.900","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國江蘇省<br/>南京市江北新區<br/>生物醫藥谷<br/>加速器二期9棟3樓","pc":"-10.39","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"159.800","isin":"CNE100006T02","moneyness":""}},"qid":"1759074078543"}
